Sri Gururangan ( Neuro -Oncology Chair ) will be responsible for providing a roadmap of the induction and salvage chemotherapy regimens to outside oncologists and acquiring documentation of all prescribed medications and any chemotherapy or procedure related toxicities during these periods. Standard medication regimens may need to be adjusted due to hematologic or other toxicities and may be managed at the discretion of the treating pediatric oncologist. Focal boost radiotherapy may be deliv ered prior to immunotherapy if required for local control. All deviations from intended regimens during induction or salvage therapy will be documented, but not considered a protocol deviation, as is within routine standard of practice for this patient population. All patients must return to the main institution for NMA conditioning regimen with cyclophosphamide and fludarabine (Group B) with PBSCT, and subsequent immunotherapy. Re-MATC H Protocol Page 62 of 106 Version: 20180628 15.4 Post-transplant Immunotherapy All patients will receive TTRNA -xALT and TTR NA-DCs as Vaccine #1. Peripheral blood will be drawn prior to non- mobilized leukapheresis , prior to immunotherapy, 1 day post Vaccine #1, 4 (+/- 1) days post Vaccine #1, weekly post Vaccine #1 for six weeks , and bimonthly , if feasible, until progression for T-cell kinetics. Blood will be processed in accordance with SOP -UFBTIP -126. DCs will be given intradermally and divided equally to both inguinal regions. Vaccines #2 and #3 will occur at 2- week intervals following the first dose.